Segui
David Parkin
David Parkin
Honorary Visiting Professor, City, University of London
Email verificata su city.ac.uk
Titolo
Citata da
Citata da
Anno
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
M Herdman, C Gudex, A Lloyd, MF Janssen, P Kind, D Parkin, G Bonsel, ...
Quality of life research 20, 1727-1736, 2011
76332011
Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis
N Devlin, D Parkin
Health economics 13 (5), 437-452, 2004
9292004
Aggregate health care expenditures and national income: is health care a luxury good?
D Parkin, A McGuire, B Yule
Journal of health economics 6 (2), 109-127, 1987
5641987
A single European currency for EQ-5D health states: results from a six-country study
W Greiner, T Weijnen, M Nieuwenhuizen, S Oppe, X Badia, J Busschbach, ...
The European Journal of Health Economics, formerly: HEPAC 4, 222-231, 2003
5382003
Economic analysis in healthcare
S Morris, N Devlin, D Parkin, A Spencer
John Wiley & Sons, 2012
5282012
Effect of computerised evidence based guidelines on management of asthma and angina in adults in primary care: cluster randomised controlled trial
M Eccles, E McColl, N Steen, N Rousseau, J Grimshaw, D Parkin, ...
Bmj 325 (7370), 941, 2002
4492002
NICE's cost effectiveness threshold
J Appleby, N Devlin, D Parkin
Bmj 335 (7616), 358-359, 2007
3092007
The influence of cost‐effectiveness and other factors on nice decisions
H Dakin, N Devlin, Y Feng, N Rice, P O'neill, D Parkin
Health economics 24 (10), 1256-1271, 2015
2822015
Assessing the performance of the EQ-VAS in the NHS PROMs programme
Y Feng, D Parkin, NJ Devlin
Quality of Life Research 23, 977-989, 2014
2662014
Measuring production efficiency of acute hospitals in Scotland, 1991-94: validity issues in data envelopment analysis
D Parkin, B Hollingsworth
Applied economics 29 (11), 1425-1433, 1997
2601997
Patient‐reported outcome measures in the NHS: new methods for analysing and reporting EQ‐5D data
NJ Devlin, D Parkin, J Browne
Health economics 19 (8), 886-905, 2010
2592010
Is there a case for using visual analogue scale valuations in cost‐utility analysis?
D Parkin, N Devlin
Health economics 15 (7), 653-664, 2006
2472006
Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation
R Thomson, D Parkin, M Eccles, M Sudlow, A Robinson
The Lancet 355 (9208), 956-962, 2000
2302000
Methods for analysing and reporting EQ-5D data
N Devlin, D Parkin, B Janssen
Springer Nature, 2020
1842020
Treatment of multiple sclerosis with interferon β: an appraisal of cost-effectiveness and quality of life
D Parkin, A Jacoby, P McNamee, P Miller, S Thomas, D Bates
Journal of Neurology, Neurosurgery & Psychiatry 68 (2), 144-149, 2000
1672000
Searching for cost effectiveness thresholds in the NHS
J Appleby, N Devlin, D Parkin, M Buxton, K Chalkidou
Health policy 91 (3), 239-245, 2009
1382009
Statistical analysis of EQ-5D profiles: does the use of value sets bias inference?
D Parkin, N Rice, N Devlin
Medical Decision Making 30 (5), 556-565, 2010
1112010
Estimating the costs of conflict and containment on adult acute inpatient psychiatric wards
C Flood, L Bowers, D Parkin
Nursing economics 26 (5), 325, 2008
1112008
Relationship between service ecology, special observation and self-harm during acute in-patient care: City-128 study
L Bowers, R Whittington, P Nolan, D Parkin, S Curtis, K Bhui, D Hackney, ...
The British Journal of Psychiatry 193 (5), 395-401, 2008
1082008
A cost-utility analysis of interferon beta for multiple sclerosis.
D Parkin, P McNamee, A Jacoby, P Miller, S Thomas, D Bates
Health technology assessment (Winchester, England) 2 (4), iii-54, 1998
1081998
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20